The report by Zion Market Research on theGlobal Stem Cell Banking Market Research Report Covers, Future Trends, Size, Share, Past, Present Data and Deep Analysis, And Forecast, 2021-2027is the finest fabrication of expertise and trust. The report elaborates the industry-wide research analysis on the dynamics of the parent industry.
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies announces the launch of human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell. These services, offered through STEMCELLs Contract Assay Services division, will provide researchers with comprehensive cell quality assessments and enable them to generate cell banks using standardized practices
1Q22 Added 19,673 New SubscribersRevenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million)Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million)OperatingIncome Up 17.3% YoY to RMB156.6 Million ($24.2 Million)Non-GAAP Operating Income Up 15.5% YoY to RMB168.5 Million ($26.1 Million)Conference Call to be Held on August 31, 2021, at 8:00 a.m. ET HONG KONG, Aug.
Cryo-Cell International, Inc. (Symbol CCEL), The Leader In Cord Blood And Cord Tissue Cryopreservation Services, Today Announced That The Companys Common Stock Has Been Approved For Listing On The Nasdaq Capital Market (Nasdaq)
DGAP-News: Vita 34 AG / Key word(s): Half Year Results31.08.2021 / 07:30 The issuer is solely responsible for the content of this announcement. Vita 34 again achieves double-digit growth in revenues and earnings in the first half of the year -Revenues increase by 13.7 percent to EUR 10.8 million- Adjusted EBITDA rises disproportionately by 20.3 percent to EUR 3.2 million- Operating cash flow and liquidity reflect positive business performance Leipzig, 31 August 2021 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), one of the largest cell banks in Europe, continued to grow in the second quarter of 2021. Once again, the targeted marketing and sales measures in the DACH region were a key driver for increasing customer demand.
Acute Exacerbation of CRS Treatment Market: Introduction According to the report, the global acute exacerbation of CRS treatment market was valued over US$ 4.33 Bn in 2020. It is projected to expand at a CAGR of 4.6% from 2021 to 2031. Rhinosinusitis is a major health issue globally.
Anthony Johnson Anthony Johnson - Board of Directors Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Companys Strategy, Technology Development, Commercialization, and Value Creation Efforts BUFFALO, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc.
According to the latest report by IMARC Group, titled Wearable Technology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, the globalwearable technology marketexhibited strong growth during 2015-2020.
The globalstem cell banking marketsize is expected to reach USD 14.48 Billion by 2028 at a CAGR of 8.7%, according to the latest report by Reports and Data. Rising number of hematopoietic stem cell transplantations, increasing application of stem cells in development of efficient therapeutics, and growing health burden of chronic and life-threatening illnesses are key factors expected to drive market revenue growth over the forecast period. Technological developments in stem cell preservation and collection techniques and increasing investment to accelerate stem cell research are also expected to drive market growth going ahead
According to the latest report by IMARC Group, titled Melatonin Supplements Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, the globalmelatonin supplements marketexhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 11% during 2021-2026. We are regularly tracking the direct effect ofCOVID-19on the market, along with the indirect influence of associated industries
Recent Comments